8-K: Hepion Pharmaceuticals Faces Nasdaq Delisting Notice Due to Stockholders' Deficit

Hepion Pharmaceuticals received a notice from Nasdaq for failing to meet continued listing requirements due to a stockholders' deficit reported in its recent quarterly filing.

Summary

• Hepion Pharmaceuticals received a delisting notice from Nasdaq on November 20, 2024.
• The notice was triggered by the company's reported stockholders' deficit of ($406,685) in its Form 10-Q for the period ended September 30, 2024.
• The company does not meet the alternative listing requirements of a minimum $35 million market value of listed securities or net income from continuing operations of $500,000.
• Hepion has 45 days to submit a plan to regain compliance with Nasdaq listing rules.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 days to demonstrate compliance.
• If the plan is not accepted, Hepion can appeal to a hearings panel.
• There is no guarantee that Hepion will maintain its listing on the Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting notice, a stockholders' deficit, and uncertainty about maintaining the Nasdaq listing. This suggests a negative outlook for the company.

Positives

• The company has 45 days to submit a plan to regain compliance.
• Nasdaq may grant an extension of up to 180 days to demonstrate compliance if the plan is accepted.
• The company has the opportunity to appeal to a hearings panel if its plan is not accepted.

Negatives

• Hepion Pharmaceuticals has received a delisting notice from Nasdaq.
• The company reported a stockholders' deficit of ($406,685).
• The company does not meet the alternative listing requirements of a minimum $35 million market value or $500,000 net income.

Risks

• There is no guarantee that Hepion will be able to regain compliance with Nasdaq listing rules.
• The company's stock could be delisted from the Nasdaq Capital Market.
• Failure to regain compliance could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company has 45 days to submit a plan to regain compliance with Nasdaq listing rules, and if accepted, may receive an extension of up to 180 days to demonstrate compliance. There is no assurance that the company will be successful in maintaining its listing.

Management Comments

• John Brancaccio, Interim Chief Executive Officer and Interim Chief Financial Officer, signed the report on behalf of Hepion Pharmaceuticals.

Industry Context

This delisting notice highlights the challenges faced by smaller pharmaceutical companies in maintaining financial stability and meeting exchange listing requirements. It is not uncommon for companies with significant research and development costs to experience periods of financial strain.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, particularly those with high R&D expenses and limited revenue.
• Companies like Galectin Therapeutics (GALT) and Viking Therapeutics (VKTX) have also faced similar listing compliance issues in the past, highlighting the commonality of this challenge in the biotech sector.
• The requirement for a minimum market value of $35 million or net income of $500,000 is a standard benchmark for Nasdaq listing, and failure to meet these criteria is a common reason for delisting notices.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Hepion Pharmaceuticals must submit a plan to regain compliance with Nasdaq listing rules within 45 days.
• The company may be granted an extension of up to 180 days to demonstrate compliance if its plan is accepted.
• The company may appeal to a hearings panel if its plan is not accepted.

Key Dates

Keywords

delisting, Nasdaq, compliance, stockholders' deficit, listing rule, Hepion Pharmaceuticals, HEPA